Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/ja01189a077 | DOI Listing |
Zhong Nan Da Xue Xue Bao Yi Xue Ban
July 2024
Department of Endocrinology &Metabolism, West China Hospital, Sichuan University, Chengdu 610041.
Cushing's disease is a rare endocrine disorder characterized by hypercortisolism. Chronic elevated cortisol levels can lead to dysfunction or complications in multiple organs of systems, including cardiovascular, glucose, and bone metabolism, severely impacting patients' quality of life and posing life-threatening risks. Surgery is the first-line treatment for Cushing's disease.
View Article and Find Full Text PDFYakugaku Zasshi
December 2024
Faculty of Pharmaceutical Sciences, Teikyo University.
This is a personal review of my chemistry research on retirement from Teikyo University. Under the guidance of Prof. Masaji Ohno of the Faculty of Pharmaceutical Sciences, The University of Tokyo, my research career started with the synthesis of water-soluble basic natural compounds, including the first artificial bleomycin showing potent molecular-oxygen activation effects and DNA binding abilities.
View Article and Find Full Text PDFMol Psychiatry
November 2024
Department of Pharmacology, School of Medicine, University of Crete, Heraklion, 71003, Greece.
Alzheimer's Disease (AD) is an incurable and debilitating progressive, neurodegenerative disorder which is the leading cause of dementia worldwide. Neuropathologically, AD is characterized by the accumulation of Aβ amyloid plaques in the microenvironment of brain cells and neurovascular walls, chronic neuroinflammation, resulting in neuronal and synaptic loss, myelin and axonal failure, as well as significant reduction in adult hippocampal neurogenesis. The hippocampal formation is particularly vulnerable to this degenerative process, due to early dysfunction of the cholinergic circuit.
View Article and Find Full Text PDFSleep Breath
December 2024
Apnimed Inc, 39 John F. Kennedy St. 4th Floor, Cambridge, MA, 02138, USA.
Background: Norepinephrine reuptake inhibitors such as atomoxetine (ato) can improve OSA by increasing pharyngeal muscle activity. Mineralocorticoid antagonists such as spironolactone, may potentiate the reduction of OSA severity and reduce blood pressure. We evaluated whether adding spironolactone to atomoxetine (ato-spiro) improved responses in hypertensive OSA patients.
View Article and Find Full Text PDFPestic Biochem Physiol
September 2024
Zhejiang Key Laboratory of Biology and Ecological Regulation of Crop Pathogens and Insects, School of Life Sciences, Huzhou University, Huzhou, Zhejiang 313000, China; Key Laboratory of Vector Biology and Pathogen Control of Zhejiang Province, School of Life Sciences, Huzhou University, Huzhou, Zhejiang 313000, China; Department of Biology, Lund University, Lund 223 62, Sweden. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!